A new cover for SUPER AGERS after making the NYT bestseller list. Thanks to you for making it the #1 ranked new non-fiction book on Amazon.
https://t.co/2LU5uH821R
Moving on to preventing cancer with vaccines
With today's @NEJM publication of the melanoma treatment vaccine success https://t.co/zXMF7IMuLA
The editorial notes the remarkable potential for vaccines to prevent cancer:
https://t.co/zXMF7IMuLA
"a vaccine against 25 recurrent mutational hotspots
in genes such as KRAS, BRAF, and PIK3CA could
target mutations found in more than 70% of
colorectal, pancreatic, uterine, and melanoma
skin cancers."
And @moderna_tx declares it's the future with an ongoing trial to prevent Lynch syndrome and more to come
https://t.co/7FlDrDmDJK,
Getting it wrong for many decades.
Since the 1950's, pacemaker leads have been placed in the right ventricle. A new randomized trial challenging that dogma found marked superiority of outcomes for pacing from the left bundle branch. https://t.co/DzMUaStZjS
A study on accelerated aging with chemotherapy for breast cancer
More aggressive chemo, improved breast cancer survival but a tradeoff of accelerated biological aging and increased risk of non-breast cancer mortality
https://t.co/YONcyOHJjP
The obesity adverse outcome story.
BMI is a poor and misleading way to quantify obesity
When the CAD-obesity definition is used, we see the increased risk of all-cause mortality (top graphs) and lesser risk for preclinical obesity (lower graphs)
@Nature
https://t.co/mxx5ENViwz
It's hard to beat @emollick for an up-to-date, independent assessment of AI, no less where we're headed. His new book is CO-EXISTENCE. We discussed that and a lot more in the new Ground Truths today
The critical role the blood brain barrier (BBB) plays in the Alzheimer's disease model, and how to modulate the BBB "transportome" and rescue brain astrocytes @CellCellPress
https://t.co/x2sBbvq1i7
Great discussion! Can’t do much better than this @emollick interview w @EricTopol to get up to speed on AI in general, and potential implications for life sciences, healthcare in particular.
Also: appreciate that Ethan talks as fast and as intensely as my kids say I do….
"Simply Aging"
A brilliant perspective on the complex (anything but simple) biology of human aging, by @VadimGladyshev@gladyshev_lab open-access @PNASNews https://t.co/wDaNy7YvhL
Setting an unattainable objective. I wish it would come true, but curing all these diseases in the next 10 years is impossible.
And I'm very optimistic about the impact of AI for improving health.
The impressive impact of strength training for preserving muscle mass while taking a GLP-1 drug for obesity, as seen in randomized trial @NatureMedicine
T=tirzepatide alone (Zepbound), T + REx=drug with resistance exercise
https://t.co/yLDvQ1lo5z
Two of the most important opportunities for medical AI:
1. Give the gift of time to clinicians, to promote the patient-doctor relationship
2. Improve accuracy of diagnosis and treatments
Both are helped by this type of work
Excited for the launch of Gemini for Healthcare!
We’re extending the Gemini agent with specialized healthcare skills and connectors to Epic, Optum, and more, built to support HIPAA compliance.
Instead of spending hours piecing together fragmented records and policies, care teams can offload the admin burden and get time back for what matters most: patient care.
What accounts for genetic resistance to Alzheimer's disease and dementia?
Many known protective gene variants are very instructive
Feature @Nature
https://t.co/9WqGD6yyG5
The risk of blindness associated with GLP-1 drugs is ~2/100,000 people taking these drugs and properly noted by @FDA, the very rare condition known as NAION
https://t.co/1pTdr8MnfE by @AlexLJanin
Notable: Researchers from 50 institutions collaborate to find a biomarker that has the potential to detect ovarian cancer very early, even pre-malignant
A cancer not detected by the Galleri test.
An extracellular vesicle long non-coding RNA
@NatureMedicine
https://t.co/mUHNWs6m1U
https://t.co/AypMcJ9WXO
Two new randomized trials of the potent GLP-1 drug retatrutide (aka "reta") showed marked relief of knee osteoarthritis. Prior work demonstrated that some of the GLP-1 benefit for knee osteoarthritis is independent of weight loss.
#AHA26@NEJM
https://t.co/PTS9WuTnQg